Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia-Lymphoma, Adult T-Cell 1

Interventions

mogamulizumab 3Cyclophosphamide 3Lenalidomide 2Alemtuzumab 2ruxolitinib 1peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1denileukin diftitox 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia-Lymphoma, Adult T-Cell × Raltegravir Potassium × Clear all
NCT01000285 2017-03-28

ATLL

Washington University School of Medicine

Phase 1/2 Completed
18 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡